Share on: 
Website: Immunocore
Business Area(s): 

Develops ImmTAC® (Immune mobilising monoclonal TCRs against cancer). These molecules are a new class of bi-specific biologics designed to overcome the limitations of other immuno-oncology agents by combining a T cell receptor (TCR)-targeting system with an anti-CD3 effector function to activate a highly potent and specific T cell response to cancer cells.

Career Page(s): 
Immunocore UK
Abingdon OXF
United Kingdom
Immunocore US
Conshohocken PA
United States